Breaking News, Collaborations & Alliances

Alivexis, Melodia Enter Exclusive License Agreement for MDI-0151

Will leverage their respective expertise in drug discovery R&D with the aim of obtaining clinical Proof of Concept in multiple indications.

Author Image

By: Charlie Sternberg

Associate Editor

Alivexis Inc. and Melodia Therapeutics AG, a company established by Forty51 Ventures, have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis’ MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential. MDI-0151 is an innovative clinical candidate identified in Alivexis’ MOD-A discovery program.   Melodia will rapidly initiate IND-enabling activities for MDI-0151 to prepare for a Phase 1/Phase 2a study in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters